Dofequidar Fumarate (MS-209) in Combination With Cyclophosphamide, Doxorubicin, and Fluorouracil for Patients With Advanced or Recurrent Breast Cancer
- 1 February 2007
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 25 (4), 411-417
- https://doi.org/10.1200/jco.2006.08.1646
Abstract
Purpose: To evaluate the efficacy and tolerability of dofequidar plus cyclophosphamide, doxorubicin, and fluorouracil (CAF) therapy in comparison with CAF alone, in patients with advanced or recurrent breast cancer. Dofequidar is a novel, orally active quinoline derivative that reverses multidrug resistance. Patients and Methods: In this randomized, double-blind, placebo-controlled trial, patients were treated with six cycles of CAF therapy: 28 days/cycle, with doxorubicin (25 mg/m2) and fluorouracil (500 mg/m2) administered on days 1 and 8 and cyclophosphamide (100 mg orally [PO]) administered on day 1 through 14. Patients received dofequidar (900 mg PO) 30 minutes before each dose of doxorubicin. Primary end point was overall response rate (ORR; partial or complete response). In total, 221 patients were assessable. Results: ORR was 42.6% for CAF compared with 53.1% for dofequidar + CAF, a 24.6% relative improvement and 10.5% absolute increase (P = .077). There was a trend for prolonged progression-free survival (PFS; median 241 days for CAF v 366 days for dofequidar + CAF; P = .145). In retrospectively defined subgroups, significant improvement in PFS in favor of dofequidar was observed in patients who were premenopausal, had no prior therapy, and were stage IV at diagnosis with an intact primary tumor. Except for neutropenia and leukopenia, there was no statistically significant excess of grade 3/4 adverse events compared with CAF. Treatment with dofequidar did not affect the plasma concentration of doxorubicin. Conclusion: Dofequidar + CAF was well tolerated and is suggested to have efficacy in patients who had not received prior therapy.Keywords
This publication has 25 references indexed in Scilit:
- The Role of ABC Transporters in Clinical PracticeThe Oncologist, 2003
- Overcoming Multidrug Resistance in Cancer: An Update on the Clinical Strategy of Inhibiting P-GlycoproteinCancer Control, 2003
- Multidrug resistance in cancer: role of ATP–dependent transportersNature Reviews Cancer, 2002
- Chemotherapy of Metastatic Breast Cancer: What to Expect in 2001 and BeyondThe Oncologist, 2001
- Multidrug resistance (MDR) in cancerEuropean Journal of Pharmaceutical Sciences, 2000
- Current options in treatment of anthracycline-resistant breast cancerCancer Treatment Reviews, 1999
- BIOCHEMICAL, CELLULAR, AND PHARMACOLOGICAL ASPECTS OF THE MULTIDRUG TRANSPORTERAnnual Review of Pharmacology and Toxicology, 1999
- Treatment of Breast CancerNew England Journal of Medicine, 1998
- Biology of the multidrug resistance-associated protein, MRPEuropean Journal Of Cancer, 1996
- Circumvention of drug resistance with calcium channel blockers and monoclonal antibodiesPublished by Springer Science and Business Media LLC ,1989